RESUMO
In order to characterize iron-chromium oxides generated by laser irradiation on the surface of stainless steel plates, an ultraviolet-visible (UV-Vis) near-infrared (NIR) multiwavelength excitation Raman analysis has been performed using both austenitic SS304 and ferritic SS430 stainless steel samples. Raman spectra were obtained using five different excitation wavelengths from blue (455 nm) to NIR (830 nm). These measurements have allowed us to observe and identify four Raman bands, among which two have not been previously observed for iron-chromium oxides, and characterize the existence of different resonant excitation conditions for the different excitation wavelengths. For example, when using 455 nm as excitation wavelength the band at 485 cm-1 did not show up, although that when using 830 nm as excitation wavelength is a clear characteristic band for iron-chromium oxide. In addition, the dependence of the spectra profile with the excitation wavelength for films and microspheres features was observed. This experimental Raman analysis shows the importance of the excitation wavelength for the characterization of metallic oxides with different features.
RESUMO
Cervical cancer is caused by persistent high-risk human papillomavirus (HR-HPV) infection and represents the second most frequent gynecological malignancy in the world. The HPV-16 type accounts for up to 55% of all cervical cancers. The HPV-16 oncoproteins E6 and E7 are necessary for induction and maintenance of malignant transformation and represent tumor-specific antigens for targeted cytotoxic T lymphocyte-mediated immunotherapy. Therapeutic cancer vaccines have become a challenging area of oncology research in recent decades. Among current cancer immunotherapy strategies, virus-like particle (VLP)-based vaccines have emerged as a potent and safe approach. We generated a vaccine (VLP-E7) incorporating a long C-terminal fragment of HPV-16 E7 protein into the infectious bursal disease virus VLP and tested its therapeutic potential in HLA-A2 humanized transgenic mice grafted with TC1/A2 tumor cells. We performed a series of tumor challenge experiments demonstrating a strong immune response against already-formed tumors (complete eradication). Remarkably, therapeutic efficacy was obtained with a single dose without adjuvant and against two injections of tumor cells, indicating a potent and long-lasting immune response.
